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Objective: We utilized human midbrain-like organoids (hMLOs) generated from human pluripotent stem cells carrying
glucocerebrosidase gene (GBA1) and α-synuclein (α-syn; SNCA) perturbations to investigate genotype-to-phenotype
relationships in Parkinson disease, with the particular aim of recapitulating α-syn– and Lewy body–related pathologies
and the process of neurodegeneration in the hMLO model.
Methods: We generated and characterized hMLOs from GBA1/ and SNCA overexpressing isogenic embryonic stem
cells and also generated Lewy body–like inclusions in GBA1/SNCA dual perturbation hMLOs and conduritol-b-epox-
ide–treated SNCA triplication hMLOs.
Results: We identified for the first time that the loss of glucocerebrosidase, coupled with wild-type α-syn overexpression, results
in a substantial accumulation of detergent-resistant, β-sheet–rich α-syn aggregates and Lewy body–like inclusions in hMLOs. These
Lewy body–like inclusions exhibit a spherically symmetric morphology with an eosinophilic core, containing α-syn with ubiquitin,
and can also be formed in Parkinson disease patient–derived hMLOs. We also demonstrate that impaired glucocerebrosidase
function promotes the formation of Lewy body–like inclusions in hMLOs derived from patients carrying the SNCA triplication.
Interpretation: Taken together, the data indicate that our hMLOs harboring 2 major risk factors (glucocerebrosidase
deficiency and wild-type α-syn overproduction) of Parkinson disease provide a tractable model to further elucidate the
underlying mechanisms for progressive Lewy body formation.
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Parkinson disease (PD) is a progressive neurodegenerativedisorder characterized by the selective loss of midbrain
dopaminergic (mDA) neurons in the substantia nigra pars
compacta.1 The key histopathological hallmark of PD is the
presence of intraneuronal protein inclusions named Lewy
bodies (LBs), which contain α-synuclein (α-syn) fibril
deposits.2–4 However, the etiology of LBs in PD is not fully
understood. Although LBs are widely observed in both spo-
radic and familial PD patients, it is not clear whether the for-
mation of LBs, occurring via the amplification of misfolded
α-syn fibrils, causes PD.5–7 This lack of understanding of
LBs and their contribution to disease pathogenesis may be
largely due to the absence of in vitro modeling systems that
fully recapitulate α-syn pathologies. Recent advances in
human induced pluripotent stem cell (iPSC) derivation, cul-
ture, and neuronal differentiation protocols have enabled cel-
lular modeling of brain disorders using patient-derived
iPSCs.8 However, it is challenging to establish pathological
phenotypes of PD, as pathogenesis has been attributed to
both mutations in iPSC-derived mDA neurons and environ-
mental factors. The same challenges have also been reported
in animal models, as crucial PD pathologies are largely absent
in both transgenic and knockin/knockout mouse genetic
models of disease.9 Several monogenic forms of PD have
been identified. Among these, mutations in the
glucocerebrosidase (GCase) gene GBA110 and triplication of
SNCA11 are among the most significant discoveries.
Here, we utilized human midbrain-like organoids
(hMLOs)12 generated from human pluripotent stem cells
(hPSCs) carrying GBA1 and SNCA perturbations to investi-
gate genotype-to-phenotype relationships in PD, with the par-
ticular aim of recapitulating α-syn– and LB-related pathologies
and the process of neurodegeneration in the hMLO model.
Materials and Methods
hPSC Culture and Cell Line Generation
H9 and H1 human embryonic stem cells (hESCs) were obtained
from WiCell Research Institute (Madison, WI). GM23338 and
ND34391 human iPSCs were purchased from Coriell Institute. PD
patient-derived iPSCs (GBA1-iPSC-1 and GBA1-iPSC-2; both
GBA1 N370S heterozygotes) were obtained as previously
described.13,14 The use of the commercial cell lines for in vitro
research follows our Institutional (Agency for Science, Technology,
and Research) guidelines, which do not require specific institutional
review board approval. The hESCs and iPSCs were maintained on
Matrigel-coated plates, in mTeSRTM1 (STEMCELL Technologies)
media. GBA1/ isogenic hESC lines were generated using a single
guide RNA (50-CGCTATGAGAGTACACGCAGTGG-30)
targeting exon 4 of the human GBA1 gene. For doxycycline-
inducible SNCA overexpression, hemagglutinin (HA)-tagged SNCA
cDNA was cloned into a lentiviral backbone (Addgene, Cambridge,
MA; #27150; Fig 1H) for cell infection. Cells were selected with
appropriate antibiotics from day 3 to 7, and 3 clones with over-
expression of SNCA were selected.
Generation of hMLOs
hMLOs were generated as described previously.12 Briefly, dissoci-
ated hPSCs were plated into each well of a 96-well culture plate
in neuronal induction media. Three days afterward, this medium
was changed to floorplate induction medium. On day 7, organoids
were embedded in the reduced growth factor Matrigel (Corning,
Corning, NY) and grown in tissue growth medium containing
Neurobasal and supplemented with growth factors as described
previously. Twenty-four hours after embedding, hMLOs were cul-
tured on orbital shakers for maintenance.
Lysosomal Enzyme Activity Assay
Lysosomal enzyme activity was measured from cell lysates using artifi-
cial enzyme substrates: 4MU-glucopyranoside for GCase and 4MU-
sulfate potassium salt for a-i-2-sulfate (Sigma-Aldrich, St Louis, MO).
hMLOs were harvested in activity assay buffer (0.25% [vol/vol]
Triton-X100, 0.25% [wt/vol] taurocholic acid, and 1mM
ethylenediaminetetraacetic acid in citrate/phosphate buffer [pH 5.4]),
and 10μg protein was added to 10μl of 10% bovine serum albumin
(BSA; in an activity assay buffer) followed by 20μl of 5mM enzyme-
substrate (in an activity assay buffer). The reaction was stopped by
adding an equal amount of 1M glycine, pH 12.5. Samples were
loaded onto 96-well plates, and the fluorescence signal was quantified.
Lipidomics Analysis
hMLOs were homogenized in water with 0.6% formic acid
using a Precellys 24 beadmill (Bertin Technologies, Montigny-le-
Bretonneux, France) at 4C. An equal volume of acetonitrile was
added for additional homogenization. For lipid extraction, 20μl
of ceramide/sphingoid internal standard mix (LM-6002; Avanti
Polar Lipids, Alabaster, AL) and 10μl of 14:0 phosphatidylcho-
line were added to 100μl of tissue homogenate. The mixture was
incubated with 1.2ml of high-performance liquid chromatogra-
phy (HPLC) grade methanol at 50C for 10 minutes and cen-
trifuged to pellet the precipitated protein. The pellet was dried
and reconstituted in 100μl methanol before analysis with a liquid
chromatography–mass spectrometer. Lipids were separated using
an Agilent 1260 (Agilent Technologies, Santa Clara, CA) liquid
chromatography system and a Thermo Fisher Scientific
(Waltham, MA) Accucore HILIC column (100  2.1mm, parti-
cle size = 2.6μm). Mobile phase A consisted of acetonitrile/water
(95:5) with 10mM ammonium acetate, pH 8.0, and mobile
phase B consisted of acetonitrile/water (50:50) with 10mM
ammonium acetate, pH 8.0. For the separation, the column was
equilibrated with 100% mobile phase A, increasing to 20% mobile
phase B in 5 minutes, then held for 5 minutes. The column was
finally equilibrated with 100% mobile phase A for 5 minutes. Mass
spectrometry was performed using an Agilent 6430 mass spectrom-
eter. All compounds were ionized in positive mode using
electrospray ionization. The chromatograms were analyzed using
the Agilent Masshunter Workstation software (vB.06.00).
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FIGURE 1: Generation and characterization of human midbrain-like organoids (hMLOs) and GBA1+/, GBA1/, and SNCA
overexpressing (O/E) isogenic embryonic stem cells (ESCs). (A) Schematic diagrams of a differentiation protocol to generate
hMLOs from starting population of human pluripotent stem cells (hPSCs). (B) Immunostaining of day 60 hMLOs using antibodies
against tyrosine hydroxylase (TH) and dopamine transporter (DAT), markers of mature dopaminergic neurons, with quantification
(mean  standard error of the mean [SEM]; n = 3). Scale bar = 10μm. (C) Neurons immunostained with antibodies against TH
and calbindin (top panels) or TH and GIRK2 (bottom panels) in day 90 hMLOs. Scale bar = 10μm. (D) A representative voltage
trace obtained from TH+ neurons in response to hyperpolarizing current pulse. TH+ neurons displayed rebound depolarization
(Figure legend continues on next page.)
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Immunofluorescence and Immunohistochemistry
For immunofluorescence, hMLOs were fixed in 4% paraformalde-
hyde (PFA) overnight and incubated in 30% sucrose solution in
phosphate-buffered saline (PBS) at 4C overnight and were
cryosectioned at 20μm thickness. For immunofluorescence, slides
were blocked with 3% BSA with 0.5% Triton X-100 in PBS
before primary antibody incubation. Images were taken using an
LSM 710 (Zeiss, Oberkochen, Germany) or a TCS SP8 (Leica,
Wetzlar, Germany) confocal microscope. For immunohistochemis-
try, hMLOs were fixed in 4% PFA overnight, embedded in paraf-
fin, and sectioned at 4μm thickness. Deparaffinized and hydrated
sections were stained with α-syn (1:500 dilution; AB5038; Mil-
lipore, Billerica, MA) or ubiquitin (1:100 dilution; NB300-130;
Novus Biologicals, Littleton, CO). Primary antibodies were
detected with the appropriate horseradish peroxidase (HRP)-
conjugated secondary antibody (VECTASTAIN ABC kit; Vector
Laboratories, Burlingame, CA) and developed with 3, 30-
diaminobenzidine (Sigma-Aldrich). Nuclei were counterstained
with hematoxylin (HHS16-500ml, Sigma). Images were taken on
an Eclipse Ni-E microscope (Nikon Instruments, Tokyo, Japan).
Transmission Electron Microscopy
hMLOs were fixed in 2% PFA/3% glutaraldehyde in PBS for
4 hours at 4C and postfixed with 1% OsO4 in PBS (pH 7.4)
for 2 hours at room temperature (RT), followed by washing with
deionized water twice for 10 minutes. Samples were dehydrated
through an ascending ethanol series before staining with 100%
acetone. For infiltration, 100 acetone/araldite resin mix (1:1) was
added for 30 minutes and 100 acetone/araldite resin mix (1:6)
was added to the hMLOs overnight. The pure araldite resin was
changed, and hMLOs were then transferred to an oven (40C
for 30 minutes, 45C for 4 hours, and 50C for 1 hour). The
hMLOs were subsequently embedded in a fresh resin and poly-
merized at 60C for 24 hours. Sectioning was performed using
an ultramicrotome (Leica EM UC6) at a thickness of 100nm,
and sections were collected on copper grids. Before transmission
electron microscopy (TEM), the grids were stained with lead cit-
rate. Imaging was performed using JEOL JEM-1220 and JEOL
JEM-1010 (JEOL, Tokyo, Japan). Processing and imaging of
samples were performed in a blinded manner.
Intact Cell Cross-Linking
hMLOs were dissociated and incubated in 1mM disuccinimidyl
glutarate for 30 minutes at 37C. Samples were quenched with
20mM Tris (pH 7.4) for 15 minutes at RT, and a protease inhibi-
tor cocktail (Roche Diagnostics, Indianapolis, IN) was added before
sonication for 15 seconds (1-second pulse on/off) at 10% ampli-
tude. Cell lysates were then centrifuged at 100,000  g for 1 hour
at 4C. Supernatants were collected for Western blot analysis.
Thioflavin S Staining
Thioflavin S (ThioS) staining was performed by adding 0.025%
ThioS in 50% ethanol to the hMLO sections for 15 minutes of
incubation at RT. Cells where ThioS+ signal colocalized with
α-syn were counted. At least 4 fields of view were used, and
100 to 500 cells were counted per condition or cell line. Images
were taken using a Leica TCS SP8 confocal microscope.
Flow Cytometry. Flow cytometry was performed as previ-
ously described.12 Briefly, hMLOs were dissociated,
suspended in PBS, and subjected to intracellular staining
preparation per the manufacturer’s instructions (eBioscience,
San Diego, CA); 0.15–0.2  106 cells were prepared for
each 100μl staining reaction. Flow cytometry analysis was
carried out with BD LSR Fortessa (Becton, Dickinson, and
Co, Franklin Lakes, NJ), and analysis was performed using
FlowJo (Ashland, OR). Threshold gates were drawn using
cells stained with secondary antibody only.
Cell Viability Assay
Cell viability in hMLOs was assessed using the CellTiter-Glo 3D
viability assay (Promega, Madison, WI) per the manufacturer’s
instructions.
Purification of Recombinant α-Syn Protein
The Escherichia coli BL21 (DE3) strain was induced with
0.1mM isopropyl thiogalactoside for 3 hours at 37C until an
absorbance of 0.6 was reached. Cells were pelleted, resuspended
with 20mM sodium phosphate buffer (pH 7.4) for sonication,
and boiled at 100C for 20 minutes before centrifugation at
as well as a typical sag. Scale bar = 10μm. (E) Representative traces of spontaneous action potentials from TH+ neurons. (F)
Glucocerebrosidase (GCase) activity in day 30 wild-type (W/T), GBA1+/, and GBA1/ hMLOs (mean  SEM; **p = 0.0015,
****p < 0.0001; n = 3). (G) α-Iduronate-2-sulfatase (α-i-2-sulf) activity in day 30 W/T, GBA1+/, and GBA1/ hMLOs (mean  SEM;
n.s. = no significance; n = 3). (H) Principal component (PC) analysis of lipidomics data from W/T and GBA1/ hMLOs at days 30,
60, and 90. (I) Measurement of galactosyl/glucosylceramide in W/T and GBA1/ hMLOs demonstrating the specificity of GBA1
loss-of-function (mean  SEM; *p < 0.05, **p < 0.01 ***p < 0.001; n = 3). (J) Quantitative measurements of ceramide,
dihydrosphingomyelin (DHSM), and sphingomyelin in W/T and GBA1/ hMLOs (mean  SEM; *p < 0.05; n = 3). (K) Schematic of
the use of lentiviral constructs to generate a doxycycline-inducible SNCA O/E ESC line. (L) Western blot validation of α-synuclein
(α-syn) overexpression in ESCs with and without doxycycline (Dox) treatment using specific antibodies against α-syn (17 and 19kDa,
indicating endogenous and exogenous α-syn, respectively) and hemagglutinin (HA; 19kDa). Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as a loading control. (M) Semiquantitative analysis of the Western blot data for Dox-induced
α-syn expression (mean  SEM; *p = 0.04; n = 3). BDNF = brain-derived neurotrophic factor; DAPI = 4,6-diamidino-2-
phenylindole; FGF = fibroblast growth factor; GDNF = glia-derived neurotrophic factorl pGK = phosphoglycerate kinase; rtTA =
reverse tetracycline-controlled transactivator; SHH = sonic hedgehog; SMAD = a name of a structurally similar protein family. The
abbreviation refers to the homologies to the C. elegans SMA ("small" worm phenotype) and MAD family ("Mothers Against
Decapentaplegic") of genes in Drosophila (from Wikipedia); tetO = tetracycline operator; UbC = Ubiquitin C; WNT = wingless-
related integration site; WPRE = Woodchuck hepatitis virus posttranslational regulatory element.
4 Volume 00, No. 0
ANNALS of Neurology
FIGURE 2: Characterization of midbrain identity in hMLOs. (A) Differential interference contrast images illustrating the typical
morphologies of wild-type (W/T), GBA1/, and SNCA overexpressing (O/E) human midbrain-like organoids (hMLOs) at the
indicated stages. Scale bars = 1mm. (B) Sizes of hMLOs at the indicated stages (mean  standard error of the mean [SEM]; n.s.,
no significance, **p < 0.01; n = 5). (C) Cryosections of day 30 hMLOs stained with specific antibodies against OTX2, FOXA2, and
Ki67. Scale bar = 100μm. (D) Quantifications for C (mean  SEM; n.s., no significance; n = 3). (E) Cryosections of day 60 hMLOs
stained with specific antibodies against tyrosine hydroxylase (TH), FOXA2, and LMX1A. Scale bar = 100μm. (F) Quantifications
for E (mean  SEM; *p < 0.05, **p < 0.01; n = 3). (G) Cryosections of day 60 hMLOs stained with antibodies against
γ-aminobutyric acid (GABA), NeuN, and MAP2. Scale bar = 50μm. (H) Quantification of the GABA+/NeuN+ cells (mean  SEM;
n = 3). DAPI = 4,6-diamidino-2-phenylindole.
5
Jo et al: Organoid Model of PD
10,000  g for 10 minutes. The supernatant was subjected to
anion exchange chromatography and Superdex-200 gel filtration
column chromatography. Purified α-syn was dialyzed against dis-
tilled water and lyophilized. For monomer preparation, lyophi-
lized α-syn was reconstituted by PBS, followed by ultrafiltration
using a 100,000 molecular weight cutoff centrifugal device (Pall
Corporation, Port Washington, NY).
Protein Misfolding Cyclic Amplification Assay
and Proteinase K Digestion
hMLOs were sonicated with Vibra-Cells (Sonics & Materials,
Newtown, CT) to 10% (wt/vol) solution with homogenizing
buffer (1% Triton X-100, protease inhibitor cocktail in PBS) and
centrifuged at 3,000  g. The protein concentration of superna-
tants was determined by bicinchoninic acid assay (Pierce
FIGURE 3: GBA1/ and SNCA overexpressing (O/E) human midbrain-like organoids (hMLOs) show α-synuclein (α-syn)
aggregation and apoptosis-driven neurodegeneration. (A) Cryosections of wild-type (W/T), GBA1/, and SNCA O/E hMLOs at
day 60 stained with specific antibodies against tyrosine hydroxylase (TH) and α-syn. The merged images show orthogonal Z-stack
projections (Orth. Proj.). Scale bars = 10μm. (B) Percentage of TH+ cells that have aggregated α-syn (mean  standard error of
the mean [SEM]; ****p < 0.0001; n = 3). (C) Western blots of detergent-soluble and detergent-insoluble α-syn, synphilin-1, and
glucocerebrosidase (GCase) proteins in wild-type, GBA1/ (G), and SNCA O/E (S) hMLOs. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as a loading control. (D) Quantification of changes in the compositions of insoluble protein
fractions (mean  SEM; n.s. = no significance, *p < 0.05, **p < 0.005; n = 4). (E) Fluorescence-activated cell sorting (FACS)
analysis of cells dissociated from day 60 hMLOs to quantify the percentages of CC3+/TH+ cells (mean  SEM; n = 3). A threshold
gate was drawn based on a secondary antibody-only negative control. (F) Quantification of CC3+/TH+ cells by FACS revealed a
significant increase in apoptotic midbrain dopaminergic neurons in PD-related hMLOs compared to non–Parkinson disease–
related hMLOs (mean  SEM; ****p < 0.0001; n = 3). (G) Cell viability assay for hMLOs (mean  SEM; **p = 0.005, 0.004; n = 5).
DAPI = 4,6-diamidino-2-phenylindole.
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Biotechnology, Rockford, IL). Equipment for protein mis-
folding cyclic amplification (PMCA; Qsonica, Newtown, CT)
includes microplate horn, sound enclosure, and thermoelectric
chiller. α-syn monomers were prepared up to a final 5μM con-
centration in the conversion buffer (1% Triton X-100,
150mM NaCl), and 50μl was transferred into polymerase
chain reaction tubes. Thirty micrograms of hMLO homoge-
nates were used as exogenous seeds. Three Teflon beads were
placed before adding the mixture. The samples were subjected
to cycles of 20-second sonication (amplitude = 1%) and 29
minutes 40 seconds of incubation at 37C.
For proteinase K (PK) digestion, 5μM α-syn samples were
incubated with 100μg/ml PK for 80 minutes at 37C. Samples
were resolved on 16% sodium dodecyl sulfate–polyacrylamide gel
electrophoresis gels before transfer to nitrocellulose membranes.
Membranes were probed with primary antibody overnight at 4C,
washed, and incubated with an HRP-conjugated secondary anti-
body. Image detection was performed using an Amersham Imager
600 (GE Healthcare Life Sciences, Marlborough, MA), and
Multi-Gauge (v3.0) software (Fujifilm, Tokyo, Japan).
Seeded Polymerization, Thioflavin T Binding
Assay, and TEM Imaging
PMCA products (1% wt/wt) were used as seeds and added to
α-syn monomers (200μM). Samples were incubated at 37C for
5 days with shaking. Forty microliters of 10μM recombinant
α-syn sample was added to 50μl of 10μM thioflavin T (ThioT)
solution in glycine-NaOH (pH 8.5). Fluorescence was measured
with excitation/emission (Ex/Em) of 450/490nm. For TEM
imaging of α-syn fibrils, samples were adsorbed onto 200 mesh
grids, followed by negative staining with 2% uranyl acetate for
1 minute. Prepared grids were observed with a transmission elec-
tron microscope (JEOL).
RNA Sequencing and Analysis
Total RNA was isolated using TRIzol Reagent (Invitrogen, Carlsbad,
CA) and treated with DNase I (Ambion, Austin, TX). For RNA-
sequencing (RNA-seq) library preparation, total RNA was column-
purified (PureLink RNA Mini Kit, Invitrogen), and 4μg of total
RNA was applied for the RNA-seq run according to the manufac-
turer’s protocol (TruSeq RNA Sample Preparation Kit v2; Illumina,
San Diego, CA). Samples were multiplexed and sequenced in 150
base pairs paired-end format (NovaSeq 6000, Illumina). RNA-Seq
data were mapped against hg19 with STAR-2.6.1.15 Reads were
counted using featureCounts-1.6.4.16 Rlog transformed values of the
counts and differential expression were calculated using
DESeq2-1.24.0.17 We used an adjusted p value threshold of 0.05,
and a fold change threshold of 1.5 for up- and downregulated
genes, respectively. An MA plot was created using ggplot2,18 and
heatmaps for individual genes of interest were plotted using Mor-
pheus (Broad Institute, Cambridge, MA) using a relative color
scheme. Clustering analysis was performed by computing the correla-
tion of normalized gene expression using pheatmap-1.0.12. Gene
Ontology (GO) analysis was performed with DAVID v6.8.
Results
Generation and Characterization of hMLOs from
GBA1/ and SNCA Overexpressing
Isogenic ESCs
We generated hMLOs from hPSCs based on stepwise differ-
entiation protocols that guide hPSCs toward the midbrain
floor-plate that gives rise to substantia nigra dopaminergic
neurons and progenitors (see Fig 1). Briefly, hPSCs were
directed toward neuroectodermal lineages by dual-SMAD (a
name of a structurally similar protein family) inhibition (neu-
ral induction) and patterned to FOXA2- and LMX1A-
expressing midbrain floor-plate progenitors by exogenous
treatment of wingless-related integration site (WNT), fibro-
blast growth factor (FGF) (resulting in caudalization), and
sonic hedgehog morphogens (resulting in ventralization).
Next, resulting organoids were cultured in media containing
neurotrophic factors such as glia-derived neurotrophic factor
and brain-derived neurotrophic factor, which promote neuro-
nal growth and maturation. During this time (2–3 months
after seeding), resulting hMLOs become enriched in tyrosine
hydroxylase (TH)-positive, mDA neurons expressing the
dopamine transporter and/or mDA neuron marker, GIRK2,
while being predominantly immunonegative for calbindin.
Moreover, these TH-positive neurons within the hMLOs
showed rebound action potentials with significant sag cur-
rents and rhythmic spontaneous discharges with an average
frequency of 3 to 5Hz,19,20 demonstrating the presence of
mDA neurons in hMLOs.
Next, we focused on the GBA1 gene encoding the
lysosomal enzyme GCase, whose deficiency contributes to
the accumulation of glycosphingolipids (GSLs) and the
generation of the toxic, fibrillar α-syn assemblies seen in
PD.21 A higher rate of LB pathology has been reported in
early onset PD patients with GBA1 mutations as com-
pared to those without such mutations.22 Based on these
observations, we hypothesized that GBA1 deficiency could
affect the production of toxic α-syn and trigger a neuronal
loss in our hMLOs.23 To test our hypothesis, we
established human ESC lines with GBA1 depletion using
the CRISPR/Cas9 system. Homozygous GBA1 knockout
(GBA1/) isogenic ESC lines exhibited no detectable
GCase activity, with the lysosomal enzyme activity assay
showing a drastic reduction in GCase activity in the
GBA1/ lines but relatively normal activity of another lyso-
somal enzyme (α-iduronate-2-sulfatase; see Fig 1).24,25 To
further validate features associated with the loss of GCase
activity, we performed a lipidomic analysis of
GBA1/ hMLOs to monitor global lipid changes upon the
loss of GCase activity.23 Principal component analysis plots
showed clear separation of wild-type and GBA1/ hMLOs,
and HPLC–liquid chromatography–mass spectrometry
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measurements revealed significant accumulation of GSLs and
consequent reductions in lipid species related to the galacto-
syl/glucosylceramide metabolic pathways.
To compare the effect of GCase deficiency, which
is known to induce α-syn accumulation itself,23 with that
of increased wild-type α-syn production, which has been
observed in cases of familial PD harboring SNCA gene
triplication,11 we established isogenic hESC lines that
inducibly express wild-type α-syn (SNCA overexpressing
[O/E] lines; see Fig 1K). In the presence of doxycycline,
we observed a robust expression of HA-tagged α-syn
(19kDa; see Fig 1L, M).
FIGURE 4: Presence of Lewy body–like inclusions (LBLIs) in human midbrain-like organoids (hMLOs) derived from GBA/::SNCA
over-expressing (O/E) embryonic stem cells (ESCs) in the H9 background. (A) Western blot validation of the GBA1/::SNCA O/E
ESC lines upon doxycycline (Dox) treatment using specific antibodies against α-synuclein (α-syn; 17 and 19kDa, indicating
endogenous and exogenous α-syn, respectively), glucocerebrosidase (GCase; 60kDa), and hemagglutinin (HA; 19kDa).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control. (B) Immunostaining of GBA1/::SNCA O/E
ESC clones upon Dox treatment with specific antibodies against α-syn and HA. Scale bar = 100μm. (C) Lysosomal enzyme activity
in GBA1/::SNCA O/E (mean  standard error of the mean; ****p < 0.0001; n = 3). (D) Immunostaining of LBLIs exhibiting
halolike α-syn+ immunoreactivity in tyrosine hydroxylase (TH)+ neurons of day 90 hMLOs derived from GBA1/::SNCA O/E
ESCs. Scale bars = 10μm. (E) Quantification of the diameters of the identified LBLIs (n = 10). (F) Quantification of LBLIs in
cryosections of day 90 hMLOs based on α-syn immunoreactivity. (G) Hematoxylin and eosin (H&E), immunohistochemistry, and
transmission electron microscopy (TEM) images of LBLIs. White and black arrows indicate LBLIs and nuclei, respectively, and the
arrowheads indicate α-syn fibrillar structures. Black scale bars = 5μm. White scale bar = 500nm. DAPI = 4,6-diamidino-2-
phenylindole; Orth. Proj. = orthogonal Z-stack projections (Orth. Proj.); UBQ = ubiquitin; W/T = wild type.
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Progressive Loss of mDA Neurons in
PD-Associated hMLOs
We next sought to characterize the growth rate and the
cellular lineage progression of hMLOs derived from these
isogenic hESC lines. At day 30, early stage hMLOs
derived from wild-type, GBA1/, and SNCA O/E hESCs
exhibited similar growth rates, based on their shapes and
diameters (Fig 2). By day 60, however, hMLOs derived
from GBA1/, and SNCA O/E ESCs showed reductions
in diameter of approximately 100μm. To test whether this
size reduction was due to cell loss at a specific stage, we
quantified the proportion of cells expressing both FOXA2
and OTX2 (markers that together mark midbrain neuro-
nal progenitors) that are actively proliferating (Ki67+).
Interestingly, we did not observe a decrease in the
FOXA2+/OTX2+/Ki67+ population in GBA1/ or
SNCA O/E hMLOs as compared to wild-type controls at
day 30. After 25 days of differentiation, FOXA2+ neuro-
nal progenitors began to express TH, a defining marker of
dopaminergic (DA) neurons, with the majority of
FOXA2+ cells expressing TH by day 45. Interestingly, at
FIGURE 5: Presence of Lewy body–like inclusions (LBLIs) in human midbrain-like organoids (hMLOs) from GBA1/::SNCA
overexpressing (O/E) embryonic stem cells (ESCs) in the H1 background as well as Parkinson disease patient-derived induced
pluripotent stem cells (iPSCs). (A) Schematic showing CRISPR/Cas9 genome editing to generate H1-GBA1/::SNCA O/E clones.
The gRNA targeting sequence is in green; the protospacer adjacent motif (PAM) sequence is in red. Genomic DNA sequencing
of the GBA1/ ESC line showed a homozygous 7-base pair (bp) deletion. (B) Western blot validation of α-synuclein (α-syn)
protein levels in the H1-GBA1/::SNCA O/E ESC line upon doxycycline (Dox) treatment using specific antibodies against α-syn
(17 and 19kDa, indicating endogenous and exogenous α-syn, respectively), glucocerebrosidase (GCase; 60kDa), and
hemagglutinin (HA; 19kDa). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control.
(C) Immunostaining of H1-GBA1/::SNCA O/E ESC clones upon Dox treatment with specific antibodies against α-syn and HA.
Scale bar = 100μm. (D) Immunostaining of LBLIs exhibiting halolike α-syn+ immunoreactivity in tyrosine hydroxylase (TH)+
neurons of day 90 hMLOs derived from H1-GBA1/::SNCA O/E ESCs (G::S), SNCA triplication iPSCs or control iPSCs with
conduritol-b-epoxide (CBE) treatment, and GBA1-iPSCs with and without SNCA overexpression. White arrows indicate LBLIs.
Scale bar = 5μm. (E) Immunohistochemical analyses of day 90 hMLOs derived from H1-GBA1/::SNCA O/E ESCs, SNCA
triplication iPSCs with CBE treatment, and GBA1-iPSCs with SNCA overexpression using specific antibodies against α-syn and
ubiquitin (UBQ). The white and black arrows indicate LBLIs and nuclei, respectively. Scale bar = 5μm. (F) Quantification of the
diameters of the identified LBLIs (n = 8). (G) Frequency of LBLI occurrence in cryosections of day 90 hMLOs based on α-syn
immunoreactivity. DAPI = 4,6-diamidino-2-phenylindole.
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day 60, GBA1/ and SNCA O/E hMLOs showed an
approximately 8% and 11% reduction in FOXA2+/TH+
double-positive cells, respectively. We also performed
immunostaining for other neuronal subtype markers, such
as γ-aminobutyric acid (GABA; a marker of GABAergic
neurons), choline acetyl transferase (ChAT; a marker of
cholinergic neurons), and 5-hydroxytryptamine (5-HT; a
marker of serotonergic neurons). As we previously
reported,12 we did not observe any ChAT- or 5-HT–
expressing cells in the hMLOs (data not shown). How-
ever, we found that approximately 20% of cells within the
hMLOs were positive for GABA and that the percentages
of GABA+ cells between groups were not different. Taken
together, the results showed that GBA1/ and SNCA
O/E hMLOs exhibited specific degeneration of mDA neu-
rons by day 60, whereas other cell types, including mDA
progenitors and GABAergic neurons, were unaffected.
Accumulation of α-Syn Aggregates in
PD-Associated hMLOs
Several recent studies have demonstrated that mice with
genetic ablation of Gba1 or PD-associated point muta-
tions and iPSC-derived neurons from patients harboring
GBA1 mutations exhibit increased levels of neuronal
α-syn aggregation.24,26 Consistent with these findings, we
observed increased populations of TH+ mDA neurons
with α-syn aggregates in both GBA1/ and SNCA O/E
hMLOs as compared to wild-type controls (52% of mDA
neurons in day 60 GBA1/ hMLOs and 68% of
mDA neurons in day 60 SNCA O/E hMLOs, respec-
tively; Fig 3). Next, we performed sequential detergent-
based protein fractionation and subsequent Western blot
analyses using lysates obtained from these hMLOs to
assess the levels of detergent-resistant α-syn aggregates.24
We found augmented levels of insoluble α-syn in lysates
from both GBA1/ and SNCA O/E hMLOs as com-
pared to wild-type hMLOs (2.2-fold and 2.9-fold
increases, respectively). In addition, the expression level of
synphilin-1, an α-syn–interacting protein that induces the
formation of intracellular aggregates,27 was increased only
in insoluble fractions. These data indicated that compared
to wild-type hMLOs, both GBA1/ and SNCA O/E
hMLOs exhibit enhanced accumulation of insoluble α-syn
at the same developmental stage.
Given that mDA neuron numbers were reduced sig-
nificantly in GBA1/ and SNCA O/E hMLOs at day 60,
we performed fluorescence-activated cell sorting analysis
and observed significantly higher percentages of TH+/
CC3+ cells in the mutant hMLOs (3.48, 7.87, and
13.03% on day 60 wild-type, GBA1/, and SNCA O/E
hMLOs, respectively; see Fig 3E, F). In support of this
finding, a cellular viability assay to approximate adenosine
FIGURE 6: Characterization of H9-GBA1/::SNCA
overexpressing (O/E) and H1-GBA1/::SNCA O/E human
midbrain-like organoids (hMLOs), SNCA triplication-induced
pluripotent stem cell (iPSC) hMLOs with conduritol-b-epoxide
(CBE) treatment (S-iPS-C), and GBA1-iPSC hMLOs with SNCA
overexpression (G-iPS::S). (A) Quantification of cells expressing
combinations of the midbrain progenitor markers OTX2, FOXA2,
and Ki67 in day 60 H9- and H1-GBA1/::SNCA O/E hMLOs (G::
S), SNCA triplication iPSC-derived hMLOs with or without CBE
treatment, and GBA1 mutant iPSC-derived hMLOs (mean
 standard error of the mean [SEM]; n.s. = no significance;
n = 3). (B) Quantification of cells expressing combinations of the
midbrain progenitor markers FOXA2 and LMX1A with the
dopaminergic neuron marker tyrosine hydroxylase (TH) in day
60 H9- and H1-GBA1/::SNCA O/E hMLOs, SNCA triplication
iPSC-derived hMLOs with or without CBE treatment, and GBA1
mutant iPSC-derived hMLOs (mean  SEM; ***p < 0.001; n = 3).
(C) Western blots for α-synuclein (α-syn), TH, CC3, and
glucocerebrosidase (GCase) in hMLOs derived from H9- and
H1-GBA1/::SNCA O/E hMLOs, SNCA triplication iPSC-derived
hMLOs with or without CBE treatment, and GBA1 mutant iPSC-
derived hMLOs. DAPI = 4,6-diamidino-2-phenylindole; GAPDH =
glyceraldehyde-3-phosphate dehydrogenase; W/T = wild type.
[Color figure can be viewed at www.annalsofneurology.org]
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FIGURE 7: α-Synuclein (α-syn) aggregates from GBA1/::SNCA overexpressing (O/E) human midbrain-like organoids (hMLOs)
are pathogenic. (A) Cryosections of GBA1/::SNCA O/E hMLOs at day 60 stained with specific antibodies against tyrosine
hydroxylase (TH) and α-syn. The merged images show orthogonal Z-stack projections (Orth. Proj.). Scale bars = 10μm. (B)
Quantification of the percentages of TH+ cells with α-syn aggregates. The percentage of TH+ cells containing aggregate α-syn is
shown (mean  standard error of the mean [SEM]; ****p < 0.0001; n = 3). (C) Western blots of α-syn, p-Tau, p129-α-syn, and
glucocerebrosidase (GCase) proteins in day 60 hMLOs derived from wild-type (W/T), GBA1/ (G), SNCA O/E (S), and GBA1/::
SNCA O/E ESCs. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control. (D) Western blotting was
performed to detect high-molecular-weight (HMW) α-syn. H9 isogenic hMLOs were subjected to 1mM disuccinimidyl glutarate
cross-linking before whole lysates were extracted. (E) Quantification of HMW α-syn from the experiment in D (mean  SEM; n.s.
= no significance, **p < 0.005; n = 4). (F) Schematic representation of protein misfolding cyclic amplification (PMCA) and seeded
polymerization for the thioflavin T (ThioT) binding assay and transmission electron microscopy (TEM) imaging. (G) Proteinase K
(Figure legend continues on next page.)
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triphosphate content28 showed approximately 50% reduction
in the viabilities of GBA1/ and SNCA O/E hMLOs
(see Fig 3G). Taken together, these data indicated that mDA
neurons in both GBA1/ and SNCA O/E hMLOs were
more prone to apoptosis (which could also explain the size
differences between them and wild-type controls), possibly
due to accumulations of insoluble α-syn aggregates.
Generation of LB-Like Inclusions in GBA1/SNCA
Dual Perturbation hMLOs and Conduritol-b-
Epoxide–Treated SNCA Triplication hMLOs
Previously, Taguchi et al generated Gba1 mutant (with
N370S and L444P mutations) and knockout mice and
subsequently crossed these mice with previously character-
ized human α-syn A30P transgenic models of PD.26
These mice exhibited early accumulation of GSLs in the
brain, increased fibrillar α-syn protein levels, and clinical
PD symptoms including resting tremor and progressive
motor decline but lacked LB pathology.26 Although muta-
tions in both the GBA1 and SNCA loci have not been
reported in PD patients, reductions in GCase activity, as
well as increases in pathogenic a-syn and the appearance
of LBs, have been well-documented in both familial and
idiopathic forms of the disease. In particular, heterozygous
mutations in GBA1 are significant risk factors for PD.10 It
is therefore possible that the combination of both genetic
perturbations would be valuable as an accelerated model
for recapitulating hallmarks of PD in vitro and studying
disease pathogenesis. To this end, we combined both
genetic risk factors (GBA1/ in an SNCA O/E back-
ground) to test a multi-hit pathogenic scenario for PD.
The resulting GBA1/::SNCA O/E ESC lines lacked the
GBA1 protein and GCase enzyme activity and exhibited
doxycycline-dependent α-syn expression (Fig 4). Intrigu-
ingly, we observed α-syn–containing LB-like inclusions
(LBLIs) in TH+ mDA neurons in the GBA1/::SNCA
O/E hMLOs at day 90. Although these LBLIs shared sim-
ilar spherically symmetric morphology, they were smaller
(ranging in size from 1 to 3μm) than LBs reported in PD
patients.9,29 These LBLIs were rarely observed in hMLOs
derived from either GBA1/ or SNCA O/E ESCs alone.
In addition, these LBLIs displayed key features of LBs,
such as an eosinophilic core as revealed by hematoxylin
and eosin staining, a common pathological staining
method to detect LBs in postmortem brains.29 LBs iso-
lated from PD patients have been reported to contain a
variety of proteins, including α-syn and ubiquitin.30
Immunohistochemical analyses of LBLIs revealed the pres-
ence of a peripheral halo that was immunopositive for
α-syn, with a ubiquitin-immunopositive core. TEM
showed concentric lamination in LBLIs; they were ultra-
structurally comprised of a granular core and filamentous
outer layers.29 The exclusive presence of LBLIs in
GBA1/::SNCA O/E hMLOs was striking and suggested
that GCase deficiencies in the context of increased α-syn
could accelerate the formation of LBLIs in TH+ neurons,
thus presenting a viable option for studying the mecha-
nisms and role of LB formation in PD.
To test the robustness of the LBLI phenotype, we
established another hESC line with GBA1::SNCA O/E
perturbations using the H1 hESC line and confirmed that
the cells were deficient for GCase and overexpressed HA-
tagged α-syn (Fig 5). hMLOs generated from this cell line
developed LBLIs by day 90, with LBLI sizes and occur-
rence frequencies comparable to that of LBLIs from H9
GBA1::SNCA O/E hMLOs. In addition, we tested an
alternative pharmacological inhibition of GCase using
conduritol-b-epoxide (CBE; 50μM) in hMLOs generated
from both healthy and SNCA triplication patient-derived
iPSCs.31 Following 30 days of chronic CBE treatment, we
observed a complete loss of GCase activity (data not
shown). Importantly, we observed similarly shaped LBLIs
in day 90 hMLOs from treated SNCA triplication iPSCs,
but not from similarly treated healthy iPSCs. Similar
observations were made for hMLOs from patient-derived
iPSCs harboring the GBA1 N370S mutation10; LBLIs
were only observed upon induced overexpression of wild-
type α-syn. Interestingly, compared to hMLOs without
LBLIs, all hMLOs with LBLIs showed reduced TH+
mDA neurons with increased expression of apoptotic
markers such as CC3 (Fig 6B, C), whereas the midbrain
progenitor cells did not seem to be affected (see Fig 6A).
Taken together, these results strongly suggest that both
impaired GCase function and α-syn accumulation were
crucial to the generation of LBLIs, and underscore the
value of the multi-hit model in interrogating the role of
LBLIs and potentially LBs in PD pathogenesis.
Formation of Distinct Oligomeric and Fibrillar
α-Syn Aggregates in LBLI-Forming hMLOs
To understand the molecular mechanisms underlying the
formation of LBLIs, we analyzed hMLOs at day 60, an
(PK) digestion patterns of PMCA products from day 60 hMLOs. (H) ThioT binding kinetics of seeded polymerization using PMCA
end products for each type of hMLO. (I) TEM images of seeded aggregates. Scale bars = 200nm. (J) Immunostaining for α-syn
and thioflavin S (ThioS) double-positive neurons from control, GBA1/, SNCA O/E, and GBA1/::SNCA O/E hMLOs at day 60.
The arrowheads point to the colocalization of α-syn and ThioS. Scale bar = 5μm. (K) Quantification of the immunostaining from J
(mean  SEM; ****p < 0.0001; n = 3). DAPI = 4,6-diamidino-2-phenylindole.
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FIGURE 8: Transcriptomic characterization of GBA1/ and SNCA overexpressing (O/E) human midbrain-like organoids (hMLOs).
(A) Clustering analysis of the RNA-sequencing (RNA-seq) data. The Euclidean distance of the normalized gene expression among
wild-type (W/T), GBA1/, and SNCA O/E hMLOs was used for sample clustering. (B) MA plot showing the distinct genes
differentially expressed in SNCA O/E hMLOs in the RNA-seq data set. Statistically significant differentially expressed genes
(DEGs; jfold changej ≥ 1.5, p-adj ≤ 0.05) are highlighted in red (related to Table S1). (C) Gene Ontology (GO) enrichment analysis
of DEGs dysregulated in SNCA O/E hMLOs. A heatmap representation of the DEGs (jfold changej ≥ 1.5, p-adj ≤ 0.05) known to
be associated with protein catabolism and endoplasmic reticulum stress is shown in the bottom panel (related to Table S1).
(D) MA plot showing the DEGs in GBA1/ hMLOs. Statistically significant DEGs (jfold changej ≥ 1.5, p-adj ≤ 0.05) are
highlighted in red (related to Table S1). (E) Heatmap representation of selected DEGs between W/T and GBA1/ hMLOs
(related to Table S1). (F) GO enrichment analysis of selected DEGs in GBA1/ hMLOs (select GO terms are ranked by the
adjusted p values; related to Table S2). FDR = false discovery rate; GABA =γ-aminobutyric acid.
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earlier time point prior to LBLI formation, and quantified
the numbers of α-syn aggregates, levels of phospho-Ser129
α-syn (a marker for pathologic α-syn),32 and levels of
phosphorylated tau in GBA1/::SNCA O/E organoids
(Fig 7). Interestingly, we did not observe any significant
differences between SNCA O/E and GBA1/::SNCA
O/E hMLOs. Given that prefibrillar oligomeric α-syn has
been proposed to seed and initiate the assembly of fibrillar
α-syn, we assessed the seeding abilities of α-syn multi-
meric oligomers from the various hMLO models using
an intact cell cross-linking method.13 We identified multi-
meric oligomers (60, 80, and 100kDa) as well as mono-
meric α-syn proteins, and observed high levels of
high-molecular weight α-syn oligomers in GBA1/::
SNCA O/E hMLOs as early as day 60.
Next, we adapted PMCA assays, originally devel-
oped for amplification of prion proteins, for α-syn (see Fig
7).33,34 Briefly, we prepared homogenates from each
hMLO as exogenous seeds and amplified prion fibrils by
adding recombinant α-syn monomers as substrates. Multiple
cycles of sonication and subsequent incubation resulted in
polymerization and fibrillation of α-syn; the samples were
subjected to PK digestion to degrade monomeric α-syn
and were subsequently subjected to Western blotting
and TEM. We observed that GBA1/::SNCA O/E
hMLOs exhibited accelerated fibril formation, with
more β-sheet oligomers (based on exponential increases
in ThioT fluorescence, which emits fluorescence when
it binds to β-sheet oligomers). In addition, the mor-
phology of α-syn fibrils generated from GBA1/::
SNCA O/E hMLOs was filamentous. We further tested
whether the multimeric oligomer-enriched GBA1/::
SNCA O/E hMLOs produced more fibrillar α-syn by
performing ThioS staining to label amyloidogenic
β-sheet fibrils.35 Approximately 13%, 12%, and 23% of
cells from GBA1/, SNCA O/E, and GBA1/::SNCA
O/E hMLOs, respectively, were double-positive for
α-syn and ThioS. These data suggest that GCase defi-
ciency with SNCA overexpression accelerated the forma-
tion of detergent-resistant, fibrillar α-syn, more so than
single perturbation mutants, and might account for the
formation of LBLIs.
Discussion
We have previously developed a method to derive hMLOs
from hPSCs; the resulting hMLOs exhibit distinct layers
of neuronal cells with functionally mature mDA neurons
and produce neuromelanin-like granules that are in vitro
replicas of those isolated from human substantia nigra tis-
sue.12 However, given the transcriptional resemblance of
the hMLOs to human fetal midbrains, it was not clear
whether the hMLO model could be utilized to study late
onset human midbrain disorders such as PD.
Here, we report that the genetic introduction of two
PD risk factors (loss of GCase and α-syn overexpression)
in hMLOs resulted in the recapitulation of many hallmark
features of PD, most significantly the formation of LBLIs
and the loss of mDA neurons, two key pathophysiological
hallmarks of PD.36 LBLIs were structurally and molecu-
larly similar to PD-associated LBs. For decades, multiple
animal models of PD (pathogenic models established by
neurotoxin treatment and in vivo injection of preformed
α-syn fibrils as well as gene-based, knockin/knockout
transgenic mouse models harboring familial PD muta-
tions) have been used as standard PD models for basic
mechanistic studies and drug discovery. However, these
models do not fully recapitulate human PD,37 resulting in
limited implications for disease pathogenesis. In contrast
to these models, our 3-dimensional hMLO system recapit-
ulated pathogenic cascades of PD in a more physiological
environment, which has not been demonstrated in PD
animal models or other 2-dimensional cultures of human
mDA neurons.
One of the most interesting aspects of our hMLO
PD model is the generation of LBLIs without expression
of mutant α-syn. To date, 6 different autosomal-dominant
missense mutations in SNCA (A53T, A30P, E64K,
H50Q, G51D, and A53E) have been identified; these
mutations result in α-syn adopting an oligomeric and/or
fibrillar conformation38–46 or interacting directly with
membrane phospholipids—particularly highly curved,
endogenous vesicles and organelles such as mitochondria,
the endoplasmic reticulum, and the Golgi.47 Intriguingly,
although complete GBA1 knockout alone could augment
the levels of both soluble and insoluble α-syn in our sys-
tem and induce levels of cellular α-syn aggregates compa-
rable to those in SNCA O/E hMLOs (see Fig 3C, D),
they failed to form LBLIs (see Fig 4F). This may have
been due to qualitative differences in the α-syn oligomers
derived from GBA1 knockout hMLOs as compared to
SNCA O/E organoids (see Fig 7G, H). In support of this
notion, transcriptome profiling of hMLOs using RNA-seq
also indicated that SNCA overexpression remodeled the
transcriptomic landscape much more dramatically than
GBA1 loss (differentially expressed genes [DEGs]: SNCA
O/E hMLOs: 4,821 upregulated, 2,815 downregulated;
GBA1/ hMLOs: 286 upregulated, 305 downregulated;
false discovery rate ≤ 0.05 and jfold changej ≥ 1.5; Fig 8,
Table S1). More importantly, GO analysis indicated that
the DEGs in SNCA O/E hMLOs were enriched for
biological processes such as protein catabolism, endoplas-
mic reticulum stress, ion transmembrane transport, and
lipid transport (Table S2). In contrast, the DEGs in
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GBA1/ hMLOs were implicated in synaptic transmis-
sion, ion channel function and cell division (see
Table S2). These findings support the notion that wild-
type SNCA overexpression resulted in substantial trans-
criptome changes that corroborate well with the results of
previous transcriptome analyses of PD patient brains48; in
contrast, transcriptome analysis of GBA1/ hMLOs
showed less pronounced changes in the PD-related trans-
criptome, potentially due to the biological function of
GBA1, a lysosomal enzyme that cleaves glucosylceramide
into glucose and ceramide during GSL metabolism and
lies downstream of gene transcription and modification.49
Another interesting aspect of our results is that the
genetic introduction of 2 PD risk factors (loss of GCase
activity and wild-type α-syn overexpression) resulted in
the formation of LBLIs, possibly via specific oligomeric
and fibrillar α-syn formation. Although it is unclear why
these 2 factors synergistically influence LBLI formation in
hMLOs, further proteomic/lipidomic investigation of
isolated α-syn oligomers and fibrils from LBLI-forming
hMLOs will help us to elucidate the cellular and molecu-
lar underpinnings of LB biogenesis in PD and eventually
address the physiological function(s) of LB formation in
neurons, which in turn will guide therapeutic strategies.2
In particular, it would be exciting and illuminating to test
whether rescue of GCase activity via several avenues, for
example, by activation of the autophagic–lysosomal path-
way through treatment with chemical chaperones such as
ambroxol (currently under phase 2 clinical trials), GCase
overexpression, or reduction of GCase substrates such as
glucosylceramides with compounds such as Genz-682452
(currently in phase 2 clinical trials),50 can reverse or pre-
vent the formation of LBLIs. Some success for such strate-
gies has been reported in human iPSC-derived mDA
neurons, where GBA1 overexpression decreases overall cel-
lular α-syn levels.51 Similar strategies in the dual perturba-
tion genetic model presented here could be key in
identifying therapies for the rescue of LB formation phe-
notypes in PD.
In summary, we have successfully recapitulated
α-syn and LB pathologies in a human brain organoid cul-
ture system, generated from isogenic hESCs, SNCA tripli-
cation, and GBA1 loss-of-function iPSCs. Our model can
be used to further elucidate the underlying mechanisms of
progressive LB formation as well as the selective vulnera-
bility of mDA neurons and to screen potential therapeutic
agents for PD.
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